2013 VEITHsymposium: Treating CCSVI in Patients With Multiple Sclerosis


The Particulars: Previous research indicates that multiple sclerosis (MS) is associated with chronic cerebrospinal venous insufficiency (CCSVI). Data indicate that 30,000 patients worldwide have undergone endovascular procedures to treat CCSVI since 2009. However, the safety and efficacy of these procedures has not been established in clinical trials.

Data Breakdown: In a prospective, double-blind, randomized controlled trial, researchers investigated the safety and efficacy of percutaneous transluminal venous angioplasty (PTVA) for correcting CCSVI in patients with MS. PTVA was safe and not associated with serious adverse events in the trial. However, no differences were observed in clinical symptoms, brain lesions, or quality of life between patients with MS who underwent the treatment and those who did not.

Take Home Pearls: PTVA for correcting CCSVI in patients with MS appears to be safe. However, use of the treatment does not appear to provide sustained improvement.

1 Comment

  1. I am curious as to your definition of “sustained improvement”. My improvements have lasted almost 3 years now and have been documented by neurological testing. My quality of life has sky-rocketed. Since I was declared secondary/progressive in the mid-’90’s, I was told I would NEVER improve, only progressively get worse, but they were wrong!

    From “no hope” to frisbee–all because of treatment for CCSVI!


Submit a Comment

Your email address will not be published. Required fields are marked *

16 − nine =